| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Cartesian Therapeutics, Inc. (RNAC) has 13 insiders with recent SEC Form 4 filings, including 3 buys and 28 sells. RNAC is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 8.65M | $72.80M | - | |
| 10% | 511.6K | $4.31M | - | |
| CEO | 323.5K | $2.72M | - | |
| CFO | 121.2K | $1.02M | - | |
| Other | 94.2K | $793.4K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2017 | Barabe Timothy C49 | Director | Buy | 5,000 | $9.37 | $46,840.00 | +66.8% | |
| Sep 26, 2017 | Nashat Amir | Director | Sell | 70,226 | $18.91 | $1,328,079.00 | -4.2% | |
| Sep 25, 2017 | Nashat Amir | Director | Sell | 79,211 | $19.13 | $1,515,663.89 | -2.3% | |
| Sep 21, 2017 | Nashat Amir | Director | Sell | 147,187 | $19.91 | $2,930,214.88 | -3.9% | |
| Sep 20, 2017 | Siewers David | CFO And Treasurer | Sale+OE | 16,424 | $20.00 | $328,480.00 | -100% | |
| Jul 3, 2017 | Johnston Lloyd P.74 | COO And SVP, R*d | Sale+OE | 5,959 | $19.10 | $113,806.49 | -39.6% | |
| Jun 30, 2017 | Siewers David | Chief Financial Officer | Sale+OE | 7,420 | $20.00 | $148,405.19 | -100% | |
| Jun 29, 2017 | Siewers David | Chief Financial Officer | Sale+OE | 9,652 | $20.00 | $193,041.92 | -99.6% | |
| Jun 27, 2017 | Keller Peter | Chief Business Officer | Sale+OE | 4,595 | $19.30 | $88,681.20 | -91.9% | |
| Jun 27, 2017 | Springer Timothy A49 | Director | Buy | 338,791 | $17.71 | $5,999,988.61 | +2,038% |